DMDécio Mion

Décio Mion

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Décio Mion has a total of 108 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Reduction of Sympathetic Nervous Activity With Device‐Guided Breathing

    by Silvana de Barros, Giovanio Vieira da Silva, Josiane Lima de Gusmão, Tatiana Goveia de Araujo, Decio Mion


  • Open Access

    Prevention of hypertension in patients with pre-hypertension: protocol for the PREVER-prevention trial

    by Flávio D Fuchs, Sandra C Fuchs, Leila B Moreira, Miguel Gus, Antônio C Nóbrega, Carlos E Poli-De-Figueiredo, Décio Mion, Luiz Bortoloto, Fernanda Consolim-Colombo, Fernando Nobre, et al.

    Blood pressure (BP) within pre-hypertensive levels confers higher cardiovascular risk and is an intermediate stage for full hypertension, which develops in an annual rate of 7 out of 100 individuals with 40 to 50 years of age. Non-drug interventions to prevent hypertension have had low effectiveness. In individuals with previous cardiovascular disease or diabetes, the use of BP-lowering agents reduces the incidence of major cardiovascular events. In the absence of higher baseline risk, the use of BP agents reduces the incidence of hypertension. The PREVER-prevention trial aims to investigate the efficacy, safety and feasibility of a population-based intervention to prevent the incidence of hypertension and the development of target-organ damage. This is a randomized, double-blind, placebo-controlled clinical trial, with participants aged 30 to 70 years, with pre-hypertension. The trial arms will be chlorthalidone 12.5 mg plus amiloride 2.5 mg or identical placebo. The primary outcomes will be the incidence of hypertension, adverse events and development or worsening of microalbuminuria and of left ventricular hypertrophy in the EKG. The secondary outcomes will be fatal or non-fatal cardiovascular events: myocardial infarction, stroke, heart failure, evidence of new sub-clinical atherosclerosis, and sudden death. The study will last 18 months. The sample size was calculated on the basis of an incidence of hypertension of 14% in the control group, a size effect of 40%, power of 85% and P alpha of 5%, resulting in 625 participants per group. The project was approved by the Ethics committee of each participating institution. The early use of blood pressure-lowering drugs, particularly diuretics, which act on the main mechanism of blood pressure rising with age, may prevent cardiovascular events and the incidence of hypertension in individuals with hypertension. If this intervention shows to be effective and safe in a population-based perspective, it could be the basis for an innovative public health program to prevent hypertension in Brazil. Clinical Trials NCT00970931 .


  • Open Access

    A comparison between diuretics and angiotensin-receptor blocker agents in patients with stage I hypertension (PREVER-treatment trial): study protocol for a randomized double-blind controlled trial

    by Flávio D Fuchs, Sandra C Fuchs, Leila B Moreira, Miguel Gus, Antônio C Nóbrega, Carlos E Poli-De-Figueiredo, Décio Mion, Luiz Bortolotto, Fernanda Consolim-Colombo, Fernando Nobre, et al.

    Cardiovascular disease is the leading cause of death in Brazil, and hypertension is its major risk factor. The benefit of its drug treatment to prevent major cardiovascular events was consistently demonstrated. Angiotensin-receptor blockers (ARB) have been the preferential drugs in the management of hypertension worldwide, despite the absence of any consistent evidence of advantage over older agents, and the concern that they may be associated with lower renal protection and risk for cancer. Diuretics are as efficacious as other agents, are well tolerated, have longer duration of action and low cost, but have been scarcely compared with ARBs. A study comparing diuretic and ARB is therefore warranted. This is a randomized, double-blind, clinical trial, comparing the association of chlorthalidone and amiloride with losartan as first drug option in patients aged 30 to 70 years, with stage I hypertension. The primary outcomes will be variation of blood pressure by time, adverse events and development or worsening of microalbuminuria and of left ventricular hypertrophy in the EKG. The secondary outcomes will be fatal or non-fatal cardiovascular events: myocardial infarction, stroke, heart failure, evidence of new subclinical atherosclerosis and sudden death. The study will last 18 months. The sample size will be of 1200 participants for group in order to confer enough power to test for all primary outcomes. The project was approved by the Ethics committee of each participating institution. The putative pleiotropic effects of ARB agents, particularly renal protection, have been disputed, and they have been scarcely compared with diuretics in large clinical trials, despite that they have been at least as efficacious as newer agents in managing hypertension. Even if the null hypothesis is not rejected, the information will be useful for health care policy to treat hypertension in Brazil. ClinicalTrials.gov: NCT00971165


    • 17 August 2004
      • Vol. 83  (2) , 179-81

    [Which hypertension guidelines should Brazilian physicians follow? A comparative analysis of the Brazilian, European and North American guidelines].

    by Giovanio Vieira Da Silva, Décio Mion, Marco Antônio Mota Gomes, Carlos Alberto Machado, José Nery Praxedes, Celso Amodeo, Fernando Nobre, Oswaldo Kohlmann

  • Qual a diretriz de hipertensão arterial os médicos brasileiros devem seguir? Análise comparativa das diretrizes brasileiras, européias e norte-americanas (JNC VII)

    by Giovanio Vieira da Silva, Décio Mion Júnior, Marco Antônio Mota Gomes, Carlos Alberto Machado, José Nery Praxedes, Celso Amodeo, Fernando Nobre, Oswaldo Kohlmann Júnior


  • O conhecimento de profissionais da área da saúde sobre a medida da pressão arterial

    by Cláudia Cristina Pereira Rabello, Angela Maria Geraldo Pierin, Décio Mion Jr.

    Avaliou-se o conhecimento teórico e prático de 110 auxiliares de enfermagem, 44 médicos e 25 enfermeiros, por meio de 15 questões de múltipla escolha e pela observação do procedimento da medida da pressão arterial. O percentual de acerto quanto ao conhecimento teórico foi de 32%±12% para os auxiliares de enfermagem, 44%±14% para os enfermeiros e 56%±13% para os médicos, sendo que todos foram estatisticamente diferentes entre si (p


  • Amlodipine 2.5???mg once daily in older hypertensives: a Brazilian multi-centre study

    by Décio Mion, Katia C Ortega, Marco A M Gomes, Osvaldo Kohlmann, Wille Oigman, Fernando Nobre

    The use of low-dose amlodipine has not yet been well established in the elderly. This study therefore aimed to evaluate the efficacy and tolerability of low-dose amlodipine in elderly patients with Joint National Committee VI stage I or II hypertension. Sixty-five hypertensive individuals (aged 66.3 +/- 5.3 years) received amlodipine 2.5 mg per day for 12 weeks before and after two periods of 4 weeks of placebo. At weeks 0, 12 and 16, patients were submitted to office, 24 h ambulatory blood pressure monitoring and home blood pressure measurement. Office systolic and diastolic blood pressure showed decreases at weeks 8 (153 +/- 17, 90 +/- 9 mmHg) and 12 (152 +/- 16, 90 +/- 9 mmHg) compared with weeks 0 (164 +/- 16, 99 +/- 6 mmHg) and 16 (162 +/- 19, 95 +/- 9 mmHg). During ambulatory monitoring, a decrease was observed in the average 24 h systolic and diastolic pressure at week 12 (143 +/- 13, 86 +/- 7 mmHg) compared with weeks 0 (155 +/- 15, 93 +/- 6 mmHg) and 16 (152 +/- 16, 92 +/- 8 mmHg). A daytime and night-time reduction in systolic and diastolic pressure was observed on home blood pressure monitoring at week 12 (146 +/- 16/88 +/- 8, 144 +/- 16/93 +/- 8 mmHg) compared with weeks 0 (159 +/- 17/94 +/- 8, 161 +/- 19/93 +/- 8 mmHg) and 16 (153 +/- 16/93 +/- 8, 154 +/- 17/92 +/- 8 mmHg). Adverse reactions were infrequent. Amlodipine at a dose of 2.5 mg per day showed efficacy and good tolerability in elderly hypertensives.


  • Open Access

    Hypertension in employees of a University General Hospital

    by Decio Mion Jr., Angela M. G. Pierin, Alberto P. Bambirra, Jorge H. Assunção, Juliana M. Monteiro, Roberta Y. Chinen, Roger B. Coser, Vânia N. Aikawa, Fernanda M. Cação, Mariana Hausen, et al.

    To find out the prevalence of hypertension in employees of the Hospital and relate it to social demographic variables. Blood pressure measurement was performed with a mercury sphygmomanometer, using an appropriate cuff size for arm circumference, weight, and height in a population sample of 864 individuals out of the 9,905 employees of a University General Hospital stratified by gender, age, and job position. Hypertension prevalence was 26% (62% of these reported being aware of their hypertension and 38% were unaware but had systolic/diastolic blood pressures of >140 and/or >90 mm Hg at the moment of the measurement). Of those who were aware of having hypertension, 51% were found to be hypertensive at the moment of the measurement. The prevalence was found to be 17%, 23%, and 29% (P <.05) in physicians, nursing staff, and "others", respectively. The univariate analysis showed a significant odds ratio for the male gender, age >50 years, work unit being the Institute of Radiology and the Administration Building, educational level 10 years, and body mass index >30 kg/m2. The multivariate logistic regression model revealed a statistically significant association of hypertension with the following variables: gender, age, skin color, family income, and body mass index. Hypertension prevalence was high, mainly in those who were not physicians or members of the nursing staff. High-risk groups (obese, non-white, men, low family income) should be better advised of prevention and early diagnosis of hypertension by means of special programs.